Tumour tissue transport after intraperitoneal anticancer drug delivery
暂无分享,去创建一个
[1] Patrick Segers,et al. Modelling drug transport during intraperitoneal chemotherapy , 2017, Pleura and peritoneum.
[2] S. Shany,et al. Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-β/SMAD Signaling. , 2016, Anticancer research.
[3] R. Fässler,et al. Integrin-mediated mechanotransduction , 2016, The Journal of cell biology.
[4] R. Jain,et al. Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma1 , 2016, Translational oncology.
[5] E. Ruoslahti,et al. iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. , 2016, Biomaterials.
[6] E. Förster,et al. Irradiation Does Not Increase the Penetration Depth of Doxorubicin in Normal Tissue After Pressurized Intra-peritoneal Aerosol Chemotherapy (PIPAC) in an Ex Vivo Model. , 2016, In vivo.
[7] A. Oldberg,et al. The Tyrosine Kinase Inhibitor Imatinib Augments Extracellular Fluid Exchange and Reduces Average Collagen Fibril Diameter in Experimental Carcinoma , 2016, Molecular Cancer Therapeutics.
[8] R. Giavazzi,et al. Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics , 2016, Chinese journal of cancer.
[9] A. Merlino,et al. Cisplatin binding to proteins: A structural perspective , 2016 .
[10] M. McAleer,et al. Survival and toxicity following sequential multimodality treatment including whole abdominopelvic radiotherapy for patients with desmoplastic small round cell tumor. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] M. Vannier,et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma , 2016, Pancreas.
[12] R. Holcombe,et al. Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer , 2016, Clinical Cancer Research.
[13] B. Hylander,et al. Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[14] I. Tannock,et al. Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors , 2015, Cancer science.
[15] F. Starr,et al. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer. , 2015, Cancer research.
[16] Christian Vanhove,et al. Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model , 2015, Oncotarget.
[17] E. Ruoslahti,et al. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[18] U. Nielsen,et al. Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302) , 2015, Molecular Cancer Therapeutics.
[19] Gary Box,et al. Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography. , 2015, Cancer research.
[20] P. Dankers,et al. Targeting the peritoneum with novel drug delivery systems in peritoneal carcinomatosis: a review of the literature. , 2015, Anticancer research.
[21] E. Sassaroli,et al. Modulation of the interstitial fluid pressure by high intensity focused ultrasound as a way to alter local fluid and solute movement: insights from a mathematical model , 2014, Physics in medicine and biology.
[22] Edward J. Kim,et al. Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma , 2014, Clinical Cancer Research.
[23] G. Wahl,et al. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.
[24] Urszula Zaleska-Dorobisz,et al. Ultrasound elastography - review of techniques and its clinical applications. , 2014, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.
[25] S. Peters,et al. Low-Dose Vascular Photodynamic Therapy Decreases Tumor Interstitial Fluid Pressure, which Promotes Liposomal Doxorubicin Distribution in a Murine Sarcoma Metastasis Model1 , 2014, Translational oncology.
[26] T. Oda,et al. Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1 , 2014, British Journal of Cancer.
[27] W. Solass,et al. Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. , 2014, Gynecologic oncology.
[28] I. Tannock,et al. Use of the Proton Pump Inhibitor Pantoprazole to Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the Therapy of Solid Tumors , 2013, Clinical Cancer Research.
[29] Rakesh K. Jain,et al. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels , 2013, Nature Communications.
[30] Urs Giger-Pabst,et al. Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy , 2013, Annals of Surgical Oncology.
[31] E. Young. Cells, tissues, and organs on chips: challenges and opportunities for the cancer tumor microenvironment. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[32] N. Forbes,et al. Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[33] W. Solass,et al. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Occupational Health and Safety Aspects , 2013, Annals of Surgical Oncology.
[34] J. Erler,et al. Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK , 2013, Oncogene.
[35] J. Remon,et al. Optimization of Drug Delivery Systems for Intraperitoneal Therapy to Extend the Residence Time of the Chemotherapeutic Agent , 2013, TheScientificWorldJournal.
[36] W. Solass,et al. Renal and Hepatic Toxicities After Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) , 2013, Annals of Surgical Oncology.
[37] B. Chauffert,et al. High Pressure Enhances the Effect of Hyperthermia in Intraperitoneal Chemotherapy With Oxaliplatin: An Experimental Study , 2012, Annals of surgery.
[38] I. Pastan,et al. Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[39] H. Kosmehl,et al. Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. , 2012, Cancer research.
[40] Carlos Cuevas,et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. , 2012, Cancer cell.
[41] Y. Maitani,et al. Collagenase-1 injection improved tumor distribution and gene expression of cationic lipoplex. , 2012, International journal of pharmaceutics.
[42] S Pili-Floury,et al. Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study , 2011, British Journal of Cancer.
[43] R. Bleichrodt,et al. Hyperthermia and Intraperitoneal Chemotherapy for the Treatment of Peritoneal Carcinomatosis: An Experimental Study , 2011, Annals of surgery.
[44] Rakesh K. Jain,et al. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.
[45] Anurag K. Singh,et al. Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. , 2011, Cancer research.
[46] R. Jain,et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors , 2011, Proceedings of the National Academy of Sciences.
[47] B. Chauffert,et al. Comparison of hyperthermia and adrenaline to enhance the intratumoral accumulation of cisplatin in a murin model of peritoneal carcinomatosis , 2011, Journal of experimental & clinical cancer research : CR.
[48] Erkki Ruoslahti,et al. Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs , 2010, Science.
[49] B. Chauffert,et al. Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study , 2010, Anti-cancer drugs.
[50] G. Salvesen,et al. Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma , 2009, BMC Cancer.
[51] Erkki Ruoslahti,et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.
[52] Wilson Mok,et al. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. , 2009, Biophysical journal.
[53] David Allard,et al. Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.
[54] Victor Frenkel,et al. Pulsed high intensity focused ultrasound mediated nanoparticle delivery: mechanisms and efficacy in murine muscle. , 2009, Ultrasound in medicine & biology.
[55] Valerie M. Weaver,et al. A tense situation: forcing tumour progression , 2009, Nature Reviews Cancer.
[56] Rakesh K Jain,et al. In vivo imaging of extracellular matrix remodeling by tumor-associated fibroblasts , 2009, Nature Methods.
[57] J. Au,et al. Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.
[58] M. Markman. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies. , 2008, Trends in pharmacological sciences.
[59] Michael A Henson,et al. Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. , 2008, Journal of theoretical biology.
[60] M. Flessner. Endothelial Glycocalyx and the Peritoneal Barrier , 2008, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[61] J. Houghton,et al. Tumor microenvironment: The role of the tumor stroma in cancer , 2007, Journal of cellular biochemistry.
[62] Alastair H Kyle,et al. Limited Tissue Penetration of Taxanes: A Mechanism for Resistance in Solid Tumors , 2007, Clinical Cancer Research.
[63] Michel Simonet,et al. High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis , 2006, Annals of surgery.
[64] Alex Vitkin,et al. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumors. , 2006, Cancer research.
[65] Cynthia A. Reinhart-King,et al. Tensional homeostasis and the malignant phenotype. , 2005, Cancer cell.
[66] B. Gustavsson,et al. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous Vasopressin in non-resectable pancreas cancer , 2005, Cancer Chemotherapy and Pharmacology.
[67] Y. Boucher,et al. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] A. Sundin,et al. 5-FU uptake in peritoneal metastases after pretreatment with radioimmunotherapy or vasoconstriction: an autoradiographic study in the rat. , 2005, Anticancer research.
[69] Kristian Pietras,et al. High interstitial fluid pressure — an obstacle in cancer therapy , 2004, Nature Reviews Cancer.
[70] C. Davies,et al. Collagenase Increases the Transcapillary Pressure Gradient and Improves the Uptake and Distribution of Monoclonal Antibodies in Human Osteosarcoma Xenografts , 2004, Cancer Research.
[71] Timothy W Secomb,et al. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. , 2004, Neoplasia.
[72] O. Kaalhus,et al. Radiation Improves the Distribution and Uptake of Liposomal Doxorubicin (Caelyx) in Human Osteosarcoma Xenografts , 2004, Cancer Research.
[73] Olivier De Wever,et al. Role of tissue stroma in cancer cell invasion , 2003, The Journal of pathology.
[74] Brian Seed,et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation , 2003, Nature Medicine.
[75] F. Stewart,et al. Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). , 2003, Anticancer research.
[76] D. Miklavčič,et al. Effect of hydralazine on interstitial fluid pressure in experimental tumours and in normal tissue. , 2001, In vivo.
[77] S N Gardner,et al. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs. , 2000, Cancer research.
[78] B. Chauffert,et al. Epinephrine enhances penetration and anti‐cancer activity of local cisplatin on rat sub‐cutaneous and peritoneal tumors , 1999, International journal of cancer.
[79] E. Sanidas,et al. Peritoneal expansion by artificially produced ascites during perfusion chemotherapy. , 1999, Archives of surgery.
[80] J Christodoulou,et al. Cisplatin Binding Sites on Human Albumin* , 1998, The Journal of Biological Chemistry.
[81] M. Flessner,et al. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. , 1997, Journal of the National Cancer Institute.
[82] P. Sugarbaker,et al. Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. , 1996, Anti-cancer drugs.
[83] R. Jain,et al. Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft. , 1996, Cancer research.
[84] S. Howell,et al. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[85] R. Jain,et al. Photodynamic therapy-induced alterations in interstitial fluid pressure, volume and water content of an amelanotic melanoma in the hamster. , 1994, British Journal of Cancer.
[86] S. D. De Smedt,et al. Nanomedicine‐based intraperitoneal therapy for the treatment of peritoneal carcinomatosis — Mission possible?☆ , 2017, Advanced drug delivery reviews.
[87] M. Dewhirst,et al. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. , 1997, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[88] P. Sminia,et al. Optimisation of intraperitoneal cisplatin therapy with regional hyperthermia in rats. , 1991, European journal of cancer.
[89] J G McVie,et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. , 1990, Cancer chemotherapy and pharmacology.
[90] R K Jain,et al. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.